Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P10827
UPID:
THA_HUMAN
Alternative names:
Nuclear receptor subfamily 1 group A member 1; V-erbA-related protein 7; c-erbA-1; c-erbA-alpha
Alternative UPACC:
P10827; A8K3B5; P21205; Q8N6A1; Q96H73
Background:
Thyroid hormone receptor alpha, also known as Nuclear receptor subfamily 1 group A member 1, plays a pivotal role in mediating the effects of thyroid hormones, including triiodothyronine and thyroxine. It functions as a high affinity receptor, crucial for regulating transcription either by repressing or activating gene expression. Its alternative names include V-erbA-related protein 7, c-erbA-1, and c-erbA-alpha.
Therapeutic significance:
This receptor's malfunction is linked to Hypothyroidism, congenital, non-goitrous, 6, a condition marked by growth and developmental retardation, skeletal dysplasia, and altered thyroid hormone levels. Understanding the role of Thyroid hormone receptor alpha could open doors to potential therapeutic strategies for this and related thyroid disorders.